These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 24691786)

  • 21. How do safety warnings on medicines affect prescribing?
    Mintzes B; Reynolds E; Bahri P; Perry LT; Bhasale AL; Morrow RL; Dormuth CR
    Expert Opin Drug Saf; 2022 Oct; 21(10):1269-1273. PubMed ID: 36208037
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interventions for implementation of thromboprophylaxis in hospitalized medical and surgical patients at risk for venous thromboembolism.
    Kahn SR; Morrison DR; Cohen JM; Emed J; Tagalakis V; Roussin A; Geerts W
    Cochrane Database Syst Rev; 2013 Jul; (7):CD008201. PubMed ID: 23861035
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative, cross-sectional study of the format, content and timing of medication safety letters issued in Canada, the USA and the UK.
    Bjerre LM; Parlow S; de Launay D; Hogel M; Black CD; Mattison DR; Grimshaw JM; Watson MC
    BMJ Open; 2018 Oct; 8(10):e020150. PubMed ID: 30297342
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FDA's expanding postmarket authority to monitor and publicize food and consumer health product risks: the need for procedural safeguards to reduce "transparency" policy harms in the post-9/11 regulatory environment.
    Roller ST; Pippins RR; Ngai JW
    Food Drug Law J; 2009; 64(3):577-98. PubMed ID: 19999646
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Role of Disproportionality Analysis of Pharmacovigilance Databases in Safety Regulatory Actions: a Systematic Review.
    Dias P; Penedones A; Alves C; Ribeiro CF; Marques FB
    Curr Drug Saf; 2015; 10(3):234-50. PubMed ID: 26219291
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A QRM Discussion of Microbial Contamination of Non-sterile Drug Products, Using FDA and EMA Warning Letters Recorded between 2008 and 2016.
    Santos AMC; Doria MS; Meirinhos-Soares L; Almeida AJ; Menezes JC
    PDA J Pharm Sci Technol; 2018; 72(1):62-72. PubMed ID: 29242394
    [TBL] [Abstract][Full Text] [Related]  

  • 27. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
    Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The FDA, preemption, and public safety.
    Gostin LO
    Hastings Cent Rep; 2011; 41(5):11-2. PubMed ID: 21980892
    [No Abstract]   [Full Text] [Related]  

  • 29. Impact of United States Food and Drug Administration's boxed warnings on adverse drug reactions reporting rates and risk mitigation for multiple myeloma drugs.
    Garg V; Raisch DW; McKoy JM; Trifilio SM; Holbrook J; Edwards BJ; Belknap SM; Samaras AT; Nardone B; West DP
    Expert Opin Drug Saf; 2013 May; 12(3):299-307. PubMed ID: 23480866
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reducing co-administration of proton pump inhibitors and antibiotics using a computerized order entry alert and prospective audit and feedback.
    Kandel CE; Gill S; McCready J; Matelski J; Powis JE
    BMC Infect Dis; 2016 Jul; 16():355. PubMed ID: 27449956
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Pharmacovigilance Signaling System Based on FDA Regulatory Action and Post-Marketing Adverse Event Reports.
    Hoffman KB; Dimbil M; Tatonetti NP; Kyle RF
    Drug Saf; 2016 Jun; 39(6):561-75. PubMed ID: 26946292
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Registering medicines for low-income countries: how suitable are the stringent review procedures of the World Health Organisation, the US Food and Drug Administration and the European Medicines Agency?
    Doua JY; Van Geertruyden JP
    Trop Med Int Health; 2014 Jan; 19(1):23-36. PubMed ID: 24134396
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reduced Effectiveness of Interruptive Drug-Drug Interaction Alerts after Conversion to a Commercial Electronic Health Record.
    Wright A; Aaron S; Seger DL; Samal L; Schiff GD; Bates DW
    J Gen Intern Med; 2018 Nov; 33(11):1868-1876. PubMed ID: 29766382
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rebuilding confidence in oral contraceptives: a new imperative in family planning.
    Spitzer WO
    Br J Clin Pharmacol; 1996 May; 41(5):359-63. PubMed ID: 8735675
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of Medical Device Alerts Issued by the Portuguese Medicines Agency: Scoping the Purpose of New Regulatory Recommendations.
    Pires C; Duarte D; Cavaco A
    Acta Med Port; 2021 Mar; 34(3):201-208. PubMed ID: 33971115
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reducing drug prescription errors and adverse drug events by application of a probabilistic, machine-learning based clinical decision support system in an inpatient setting.
    Segal G; Segev A; Brom A; Lifshitz Y; Wasserstrum Y; Zimlichman E
    J Am Med Inform Assoc; 2019 Dec; 26(12):1560-1565. PubMed ID: 31390471
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The evidence for the effectiveness of safety alerts in electronic patient medication record systems at the point of pharmacy order entry: a systematic review.
    Ojeleye O; Avery A; Gupta V; Boyd M
    BMC Med Inform Decis Mak; 2013 Jul; 13():69. PubMed ID: 23816138
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety-related regulatory actions for orphan drugs in the US and EU: a cohort study.
    Heemstra HE; Giezen TJ; Mantel-Teeuwisse AK; de Vrueh RL; Leufkens HG
    Drug Saf; 2010 Feb; 33(2):127-37. PubMed ID: 20082539
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The reorganisation of European pharmacovigilance. Part 2. From spontaneous reports to agency reviews and decisions.
    Prescrire Int; 2015 Feb; 24(157):50-4. PubMed ID: 25802924
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.